Vivimed Labs Ltd Shares Plunge to Lower Circuit Amid Heavy Selling Pressure

Market Performance and Price Action

On 10 Feb 2026, Vivimed Labs Ltd (Stock ID: 612893) recorded a maximum daily loss of 3.06%, closing at ₹7.29 after touching a low of ₹7.15. The stock’s price band was set at ₹5, with the high for the day at ₹7.82. This decline was sharper than the pharmaceutical sector’s modest gain of 0.42% and the Sensex’s 0.36% rise, signalling significant underperformance.

The stock’s trading volume was substantial, with 7.306 lakh shares changing hands, generating a turnover of ₹0.54 crore. Despite this liquidity, the stock faced persistent selling pressure, which pushed it to the lower circuit limit, indicating a temporary trading halt to curb further losses.

Technical Indicators and Moving Averages

Vivimed Labs is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning highlights a bearish trend and weak investor sentiment. The stock’s inability to sustain levels above these averages suggests that short-term and long-term momentum remain negative.

Adding to the bearish outlook, the delivery volume on 9 Feb surged to 9.32 lakh shares, a 169.38% increase compared to the five-day average delivery volume. This spike in delivery volume indicates rising investor participation, but predominantly on the sell side, as reflected in the price decline and circuit hit.

Investor Sentiment and Market Cap Considerations

Vivimed Labs Ltd is classified as a micro-cap stock with a market capitalisation of approximately ₹62 crore. Its Mojo Score currently stands at 24.0, reflecting a Strong Sell rating, an upgrade in severity from the previous Sell grade assigned on 5 Feb 2026. This downgrade signals deteriorating fundamentals and heightened risk for investors.

The stock’s market cap grade is 4, indicating limited scale and liquidity compared to larger peers. While the stock remains liquid enough to support trades of ₹0.01 crore based on 2% of the five-day average traded value, the persistent downward pressure and unfilled supply at lower price points have created a challenging trading environment.

Sectoral and Broader Market Context

The pharmaceutical and drugs sector has generally shown resilience, with a 0.42% gain on the day, supported by steady demand and positive industry trends. However, Vivimed Labs’ sharp underperformance relative to its sector peers highlights company-specific concerns, possibly linked to earnings outlook, regulatory issues, or operational challenges.

In contrast, the Sensex closed higher by 0.36%, buoyed by gains in large-cap stocks and positive macroeconomic cues. Vivimed Labs’ failure to participate in this broader market rally underscores the stock’s vulnerability and the cautious stance adopted by investors.

Unfilled Supply and Panic Selling Dynamics

The lower circuit hit is often a symptom of panic selling, where sellers overwhelm buyers, causing the stock price to fall to the maximum permissible limit for the day. In Vivimed Labs’ case, the unfilled supply at lower price levels suggests that demand has dried up, and sellers are aggressively offloading shares amid negative sentiment.

This scenario can trigger further selling pressure in subsequent sessions if no positive catalysts emerge. Investors should be wary of the risks associated with such micro-cap stocks, where volatility and liquidity constraints can exacerbate price swings.

Outlook and Investor Guidance

Given the current technical weakness, negative momentum, and strong selling pressure, Vivimed Labs Ltd remains a high-risk proposition for investors. The strong sell rating and recent downgrade reflect concerns over the company’s near-term prospects and market positioning.

Investors should closely monitor upcoming corporate announcements, quarterly results, and sector developments to reassess the stock’s outlook. Until there is a clear reversal in trend or fundamental improvement, caution is advised, especially for those with low risk tolerance.

For traders, the lower circuit hit may present short-term volatility opportunities, but the lack of buyer interest and persistent supply suggest limited upside in the immediate term.

Summary

Vivimed Labs Ltd’s plunge to the lower circuit on 10 Feb 2026 highlights the challenges faced by micro-cap pharmaceutical stocks amid volatile market conditions. Heavy selling pressure, unfilled supply, and a deteriorating technical setup have combined to push the stock down by over 3% on the day, underperforming both its sector and the broader market. The strong sell rating and recent downgrade reinforce the need for investors to exercise caution and consider alternative opportunities with stronger fundamentals and liquidity profiles.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →